The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 ...

The integration of Bruton tyrosine kinase (BTK) inhibitors into first-line treatment regimens, in combination with immunochemotherapy, constitutes the new standard of care following the recent ...

Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year before it entered the second part of a phase 1/2 lymphoma study. | Regeneron has given up on a CAR-T candidate acquired ...

By analyzing the tumor environment of diffuse large B-cell lymphoma (DLBCL), researchers from The University of Texas MD Anderson Cancer Center have identified seven distinct cellular ...

The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...

Human interleukin-26 (IL-26) is linked to intestinal inflammation and is bactericidal in vitro. This study uses zebrafish as ...

The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

Age-related changes in blood stem cells are linked to decreased platelet factor 4, marking a critical finding for treating ...